Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Receivables of $43000.0 for Q1 2026, down 45.57% year-over-year from $79000.0 in Q1 2025, and up 16.22% quarter-over-quarter from $37000.0 in Q4 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Receivables history runs 5 years deep, the most recent figure standing at $43000.0 for Q1 2026.
- In Q1 2026, Receivables fell 45.57% year-over-year to $43000.0; the TTM figure through Mar 2026 stood at $43000.0 (down 45.57% YoY), while the FY2025 annual figure was $37000.0, down 50.67% from the prior year.
- Receivables for Q1 2026 stood at $43000.0, up from $37000.0 in the prior quarter.
- The five-year high for Receivables was $1.2 million in Q4 2022, with the low at $11000.0 in Q3 2023.
- The 5-year median for Receivables is $61000.0 (2023), against an average of $154416.7.
- The sharpest annual moves came in 2023 and 2024: Receivables sank 95.58% in 2023, then soared 1172.73% in 2024.
- Corvus Pharmaceuticals' Receivables stood at $1.2 million in 2022, then tumbled by 95.58% to $52000.0 in 2023, then soared by 44.23% to $75000.0 in 2024, then sank by 50.67% to $37000.0 in 2025, then increased by 16.22% to $43000.0 in 2026.
- Business Quant data shows CRVS's Receivables at $43000.0 in Q1 2026, $37000.0 in Q4 2025, and $32000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | 6,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6,000.00 |
| Mar 31, 2026 | 43,000.00 |
| Dec 31, 2025 | 37,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 86,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 52,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Sep 30, 2023 | 11,000.00 |
| Dec 31, 2022 | 1.18 Mn |